Adult t-cell leukemia/ lymphoma: from epidemiology to treatment
International Journal of Development Research
Adult t-cell leukemia/ lymphoma: from epidemiology to treatment
Received 07th September, 2019; Received in revised form 19th October, 2019; Accepted 28th November, 2019; Published online 31th December, 2019
Copyright © 2019, Liniker Scolfild Rodrigues da Silva et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Adult T-cell leukemia/lymphoma is a lymphoproliferative disorder of mature T cells caused by humain T-cell lymphotropic virus1, the clinical features of the disease can vary greatly. Patients with adult T-cell leukemia/lymphoma have a poor prognosis because of cell resistance to conventional intensive chemotherapy and severe immunosuppression. The combination of Zidovudine and Interferon- is highly effective in the leukemic subtypes and should be considered as standard first-line therapy in that setting. Adult T-cell leukemia/lymphoma patients still benefit from chemotherapy induction with concurrent or sequential antiretroviral therapy with Zidovudine / Interferon.
